GlassScriptPhysician profile
Joel C Phillips
NPI 1114013570
$2,793.94
in general payments reported to CMS, 2019-2025
31 companies · $586 in 2025
The $586 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217 · 2020: $187 · 2021: $184 · 2022: $367 · 2023: $388 · 2024: $865 · 2025: $586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,606 · Education: $233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,606.05 |
| Education | $232.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $439.70 | 2019-2025 | |
| Janssen Biotech, INC. | $400.12 | 2021-2025 | Tremfya |
| Lilly USA, LLC | $244.78 | 2019-2025 | Taltz, Ebglyss |
| Amgen INC. | $230.41 | 2020-2025 | Otezla, Enbrel |
| Incyte Corporation | $221.33 | 2022-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $186.36 | 2020-2025 | Ilumya |
| Pfizer INC. | $162.90 | 2019-2025 | |
| Genzyme Corporation | $144.58 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $121.89 | 2019-2025 | |
| Ucb, INC. | $86.88 | 2024-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $84.04 | 2019-2025 | Jublia, Cabtreo, Siliq |
| Botanix Sb INC | $65.23 | 2025 | Sofdra |
| Leo Pharma INC. | $55.74 | 2024 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.12 | 2022-2025 | Spevigo |
| Misonix INC | $45.11 | 2020-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $32.15 | 2020-2025 | Nemluvio |
| Biofrontera INC. | $31.55 | 2022-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Genentech USA, INC. | $19.82 | 2024 | Erivedge |
| Arcutis Biotherapeutics, INC. | $19.36 | 2025 | Zoryve |
| Mayne Pharma Commercial LLC | $18.37 | 2023 | |
| Aclaris Therapeutics, INC. | $15.41 | 2019 | |
| Verrica Pharmaceuticals INC. | $15.35 | 2025 | Ycanth |
| Journey Medical Corporation | $14.25 | 2024 | |
| Dusa Pharmaceuticals, INC. | $14.05 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.80 | 2023 | Sotyktu |
| Celgene Corporation | $13.03 | 2019 | |
| Strata Skin Sciences, INC. | $12.37 | 2022 | |
| Promius Pharma LLC | $12.29 | 2019 | |
| Novum Pharma, LLC | $11.38 | 2019 | |
| Organon LLC | $7.55 | 2025 | |
| Prugen, INC. Pharmaceuticals | $6.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.